Phillip P. Chan: Yes. So CytoSorb is sold in fact all over the world with the notable exception of the United States, Japan and China. But for example, we are in most of the — I think if not all of the European Union countries. We’re in many countries in Southeast Asia, for example, Singapore, Thailand, Vietnam, Hong Kong, South Korea, etcetera. We’re in Russia. We’re in many countries in the Middle East. We are in Australia, New Zealand. We are in India, and we are in many countries in Latin America. So in fact and we also have a footprint in South Africa as well. So not that much in Africa, notable exceptions of the U.S, Canada, Japan and China, but otherwise we have a fairly broad footprint around the world. Where we leverage our EU approval to be able to sell in these countries.
Thomas Kerr: Got it. Okay. Yes, I wasn’t quite sure about that. And on the quarterly burn rate for 2024, it used to be sort of in the $4 million to $4.5 million range. With all the cost savings initiatives, will it fall below that, do you think in 2024 on a quarterly basis?
Phillip P. Chan: Kathy, do you want to take that?
Kathleen Bloch: Yes. So yes, you won’t see the full impact of the cost cutting measures in the first quarter of the year because there are sometimes some severance or other costs associated with the implementation. But you can expect our cash burn to be reduced to something around the order of $3 million a quarter in the last two quarters of the year.
Thomas Kerr: Okay. And that I was just a little surprised you finished up to support the drug ATR development and that sort of stuff, so that’s still going to be covered, I’m assuming.
Phillip P. Chan: We actually still have clinical trial costs in terms of winding down STAR-D, winding down STAR-T. And we also have clinical programs ongoing such as the COSMOS registry, our STAR registry and our PROSYS randomized controlled trial that is running in Germany. So there is still significant clinical spend that we are undertaking in 2024. But that being said, the burn will be dramatically lower than it was last year. And our goal is to obviously, as Kathy mentioned in her presentation, cash conservation is key, right. And I think we detailed many cost cutting efforts, not just a 15% workforce reduction, but cutting non-essential programs, particularly on the R&D side, as well as things even like a third year of salary freezes for executives, for example.
And so there’s a lot of things across the board that we’ve been doing in this challenging financing environment. But we hope that with additional operational progress this year that the value in our company begins to be unlocked and allows us to capitalize upon that.
Thomas Kerr: Got it. That makes sense. And last question, do you have a current share count? Because I don’t see the 10-K filing unit on the SEC website or your website.
Phillip P. Chan: Kathy, do you have that number?
Kathleen Bloch: Yes. So our common shares outstanding right now are 54.2 million and then in addition, we have options, warrants and RSUs, which bring our fully diluted common shares outstanding to 67.9 million. And I can send you that breakdown if it would help you, Tom.
Operator: There are no further questions at this time. I would like to turn the call back to management for any additional or closing remarks.
Phillip P. Chan: Well, thank you everyone for joining the call today. If you do have any other questions, please feel free to reach out to Kathy Bloch at kbloch@cytosorbents.com, and we will reply to your questions where possible. We look forward to the next quarterly call. Thank you everyone very much. Have a good night.
Operator: Thank you. That concludes our conference for today. I’d like to thank everyone for their participation. You may now disconnect.
